

## Fosun Newsletter

February-March 2016

生长  
THRIVING  
— 强健CIPC生态系统 —  
STRENGTHENING CIPC ECOSYSTEM

## Highlight


## Stock Information (As at 31 March 2016)

Stock Price.....HKD 11.04  
52-week range.....HKD 9.37-21.50  
Total shares (mn shares).....8,607.03  
Market Value (HKD bn).....95.02



RMB(billion)

BV Adjust BV



## Fosun Announces 2015 Annual Results

On 30 March 2016, Fosun announced its 2015 annual results. For the year ended 31 December 2015, Fosun's net assets attributable to owners of the parent reached RMB 75.253 billion, up 52.25% from end-2014. Profit attributable to owners of the parent was RMB 8.038 billion, up 17.27% year on year from 2014. With the "insurance + investment" twin-driver core strategy, Fosun has accomplished major improvements on both the financing end and asset end as well as the optimization of the overall asset structure. The twin-driver empowered by the "Insurance Oriented Comprehensive Financial Capability" and "Global Industrial Integration Capability Taking Roots in China" has been much strengthened than ever.

## Integrated Finance

## Insurance

Gross Premium Written (thousand RMB)	Yong'an P&C Insurance	Pramerica Fosun Life Insurance
January 2016	1,037,106.30	7,781.00
February 2016	552,417.20	2,499.20
<b>January - February 2016</b>	<b>1,589,523.50</b>	<b>10,280.20</b>

Note: Fosun Insurance Portugal, Peak Re, Ironshore and MIG don't announce the monthly gross premium written.

## Industrial Operations

## Fosun Pharma Announces 2015 Annual Results

Fosun Pharma announced its 2015 annual results on 29 March 2016. Fosun Pharma recorded revenue of RMB 12,502.16 million and net profit attributable to owners of parent of RMB 2,460.09 million, up by 4.72% and 16.43% over 2014, respectively. In terms of each business segment, revenue of pharmaceutical manufacturing and R&D business segment was RMB 8,842.66 million, revenue of health care service business segment was RMB 1,377.35 million, and revenue of medical diagnosis and medical devices business segment was RMB 2,244.37 million, representing a year-on-year increase of 16.20%, 16.17% and 16.23%, respectively.

## Industrial Operations

### Fosun Pharma Announced RMB538 Million Investment on the Restructuring of Xuzhou Coal Mining Group's Hospital

On 22 February 2016, Fosun Pharma announced that it had entered into a health industry restructuring agreement with Xuzhou Coal Mining Group Corporation and Taikang Life Insurance Co.Ltd. These three parties plan to establish a new joint venture to collaboratively conduct the restructure of Xuzhou Coal Mining Group Corporation's healthcare institutions. Fosun Pharma's investment is no more than RMB538.46 million, which would account for 35% shareholding of the joint venture. This cooperation will optimize the healthcare resources allocation of the restructured assets, and optimize the regional footprint allocation of Fosun Pharma's healthcare services by the synergies between the restructured assets and the Fosun Pharma's original healthcare services presence, which lay a solid foundation for setting up a regional healthcare center and establish the macro health industry chain.

### Fosun Pharma Issued CNY3,000,000,000 Corporate Bonds

On 7 March 2016, Fosun Pharma announced that it had finished the first public issuance of corporate bonds of 2016. The basic size of this issuance was CNY 1.5 billion and Fosun Pharma could over allot no more than CNY 1.5 billion. The final size of this issuance was CNY 3 billion with a nominal interest rate of 3.35% based on the generally optimistic belief about Fosun Pharma's future. This is a five-year bond with an option that the issuer can improve the nominal interest rate and an option of selling back for investors. The fund raised by the bonds is mainly used to adjust the debt structure and supplement working capital for the Company. This bond rating is AAA and the corporation's credit rating is AAA.

## Forte

	Attributable Sales GFA (sq.m.)	Attributable Sales Amount (RMB mn)
February 2016	48,562	844
March 2016	126,271	1,403
<b>January – March 2016</b>	<b>265,936</b>	<b>3,718</b>

## Investment

### Fosun Completes the Disposal of Equity Interest in BHF KB

On 23 February 2016, Fosun announced it had completed the disposal of all the shares of BHF KB. All of the 37,838,980 shares of BHF KB indirectly held by the Group (representing approximately 28.61% of the total issued share capital of BHF KB) was disposed at a price of EUR7.75 per share with a total sales price of EUR217,574,135. As a result the Group no longer holds, either directly or indirectly, any share in BHF KB. The directors thought the Oddo et Cie's acquisition offer provided a good opportunity to achieve gains from the Group's investment in BHF KB. After the proposed disposal, Fidelidade and Billion Infinity expected to record a profit before tax of EUR13 million and EUR35million respectively according to the balance between purchasing prices and selling prices (not including the transaction cost). Thus, the profit attributable to owners of the parent will increase by EUR29 million approximately based on the consolidated standard (not including the tax). The Group will apply the proceeds which were gained from the proposed disposal by Billion Infinity to repaying the existing loans and for general corporate capital purpose, while Fidelidade will apply the proceeds for general corporate capital purpose. The Group will continue to adhere to the "value-investing" philosophy, and we look forward to more opportunities of value investments in Germany and the broader European market.

## Contact Us

### Disclaimer

This document herewith includes forward-looking statements. All statements, other than statements of historical data, that address activities, events or developments that Fosun International Limited and its portfolio companies expect or anticipate will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The company's actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risk and factors beyond our control. In addition, the Company makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements.